Bristol-Myers Squibb Company BMY has entered into a definitive agreement with clinical-stage biopharmaceutical company, MyoKardia MYOK in a bid to acquire the latter for $225 per share in cash or a total value of $13.1 billion. The deal is expected to close in the fourth quarter of 2020 and approved by the boards of directors of both companies.

Per the agreement, a subsidiary of Bristol Myers will begin a tender offer to acquire all the outstanding shares of MyoKardia’s common stock. Following the successful closing of the tender offer, Bristol Myers will acquire all the remaining shares of MyoKardia that are not proposed in the tender offer through a second-step merger at the same price of $225 per share.

The transaction is subject to customary closing conditions and the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

The deal, if successful, will strengthen Bristol Myers’ cardiovascular franchise as MyoKardia develops targeted therapies for the treatment of serious cardiovascular diseases.

MyoKardia’s lead therapeutic candidate mavacamten, a potential first-in-class cardiovascular medicine, is being developed for the treatment of obstructive hypertrophic cardiomyopathy (HCM). A new drug application for mavacamten to treat obstructive HCM is expected to be filed in the first quarter of 2021 in the United States.

With this acquisition, Bristol Myers will add mavacamten to its portfolio and explore the full potential of the same for additional indications, such as non-obstructive HCM. The company will also gain MyoKardia’s two clinical-stage novel therapies, namely danicamtiv and MYK-224 developed for cardiovascular treatment.

Shares of Bristol Myers have declined 8.5% so far this year compared with the industry’s decrease of 3%.

We note that Bristol-Myers is highly active on the acquisition front. The company is looking to counter the generic threat to its key drugs through deal wins and